

I. AMENDMENTS

IN THE CLAIMS

Cancel claims 1-9, 11, 12, 14, 22, 23, and 25-31 without prejudice to renewal.

1.-31. (Canceled)

32. (Previously presented) A pharmaceutical composition comprising:

(a) a nucleic acid comprising a hexameric nucleotide sequence of the formula 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-Pyrimidine-3' or 5'-Purine-Purine-[Y]-[Z]-poly(Pyrimidine)-3';

where Y is any naturally occurring or synthetic nucleotide except cytosine and Z is any naturally occurring or synthetic nucleotide, wherein when Y is not guanosine or inosine, Z is guanosine or inosine, wherein the nucleic acid is 6 nucleotides to 45 nucleotides in length; and

(b) a pharmaceutically acceptable carrier.

33. (Previously presented) The composition according to claim 32 where Y is guanosine or inosine.

34. (Previously presented) The composition according to claim 32 where Y is inosine and Z is inosine or guanosine.

35. (Previously presented) The composition according to claim 32 where Y is guanosine and Z is guanosine or an unmethylated cytosine.

36. (Previously presented) A pharmaceutical composition comprising :

(a) a nucleic acid comprising a hexameric nucleotide sequence AAGGTT, wherein the nucleic acid is 6 nucleotides to 45 nucleotides in length; and

(b) a pharmaceutically acceptable carrier.

37. (Previously presented) The composition according to any one of 32-36, wherein the nucleic acid is conjugated to a peptide.